Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

Because life expectancy and the prevalence of risk factors such as hypertension, obesity and diabetes are rising globally, heart failure (HF) is growing into a major health problem. Impairment of left ...

To distinguish the two groups, you really need to see the echocardiogram and the measurement of LVEF. "That doesn't preclude that these medications could have a longer-term benefit—maybe the ...

AI echocardiography using multimodal right ventricular assessment predicted mortality in pulmonary hypertension. Learn more.

Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...

Please provide your email address to receive an email when new articles are posted on . Cumulative exposure to increased BP from early adulthood on may influence right ventricular dysfunction in ...

Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...